The Board of Directors of Ranbaxy Laboratories Limited (RLL) at their meeting held today, took on record the unaudited results for the quarter ended September 30, 2006. The Company also announced the Consolidated Global Results for the quarter (Q3) and nine months ended September 30, 2006 (YTD Sept.).

The Board also approved the payment of an interim dividend of 50% (@ Rs 2.50  per share of par value of Rs 5 each) for the year ending December 31, 2006.

Operational Highlights for the Quarter

·  Financial performance strengthens for third successive quarter in a row

·  Profit After Tax (PAT) at Rs. 1,404 Mn, up by 651%

·  Consolidated Sales up 26% at Rs. 16,404 Mn  (Excluding Allied Business

divested at end of last year, the sales growth is 30 %)

·  EBIDTA margins at 16.4% to sales versus 3.3% in the corresponding

quarter

·  US sales register 25 % growth, at USD 96 Mn; Ranbaxy’s Simvastatin

Tablets 80 mg, continue to dominate the market with over 50%  market share.

·  ANDA filings in the USA well on track with 9 filings and 3 approvals

·  BRICS markets record 38% increase in sales at USD 139 Mn; Strong

growth in CIS & India.

·  Company achieves Number 1 position in domestic market with highest

market share (Source: ORG – IMS August ‘06); Growth exceeds that of

market (Source: ORG-IMS, YTD Aug’ 06)

·  Ranbaxy Invalidates Pfizer’s ‘995 Lipitor U.S. Patent.  U.S. Court of Appeals

for the Federal Circuit (CAFC) overturns earlier District Court ruling on same

patent.  The Company  now has the opportunity to bring the launch date

forward to March 2010 from June, 2011 with  a 180-day exclusivity.

 · Company enters Oncology therapeutic area in key geographies with a

strategic investment in  Zenotech  Laboratories Limited, Hyderabad, India

·  Company enhances in-house API manufacturing capacity with acquisition of

Cardinal Drugs, based in Gwalior, India

·  Terapia Ranbaxy’ emerges as fastest growing company in Romania among

the Top 10 companies

Consolidated Results (Ranbaxy Laboratories Limited and Subsidiaries)

Contd on page 2....